At Sesen Bio, we are committed to saving and improving the lives of patients with cancer. We are a late-stage clinical company advancing targeted fusion protein therapeutics for the treatment of patients with cancer. Our lead program, Vicineumâ„¢, also known as oportuzumab monatox, has completed the follow-up stage of a Phase 3 clinical trial in the US for the treatment of non-muscle invasive bladder cancer (NMIBC). Vicineum is a locally administered targeted fusion protein composed of an anti-EpCAM antibody fragment tethered to a truncated form of Pseudomonas Exotoxin A. This fusion protein design is believed to decrease the risk of toxicity to healthy tissues, thereby improving its safety.

Latest Corporate Presentation

Copyright West LLC. Minimum 15 minutes delayed.